Oncopeptides
在场
Oncopeptides 是一家在股票代码 ONCO (SE) 下上市的公司。
高管
查看带有其 13 名主要高管的组织结构图
Oncopeptides 搜索最多的简介
高管在Oncopeptides变化
- Henrik Bergentoft已作为Chief Financial Officer加入公司 (新闻发布的2023八月9号).
- Sofia Heigis 曾任 Chief Commercial Officer and Managing Director, Germany, 现升职为 Chief Executive Officer (新闻发布的2023八月8号).
创建提醒
跟踪 Oncopeptides 的高管变动
生物技术
Oncopeptides 拥有 2,274 家竞争者，其中包括 Eurofins (卢森堡)、Lonza (瑞士) 和 Adaptive Phage Therapeutics (美国(美洲))。
Popular M&A news in 生物技术
- Bruker has announced the acquisition of NanoString Technologies (公布2024四月18号).
- Vertex Pharmaceuticals has announced the acquisition of Alpine Immune Sciences (公布2024四月16号).
- Nurix Therapeutics 刚刚宣布为 175 筹款数百万美元。 (公布2024四月13号).
生物技术 行业的其他推荐联系人
消息
Oncopeptides 的最新新闻稿
- Oncopeptides releases first quarter 2024 sales - Oncopeptides
- Oncopeptides announces final terms for the fully guaranteed rights issue - Oncopeptides
- Oncopeptides and Vector Pharma FZCO Announce Collaboration to Provide Pepaxti to Patients in the Middle East and North Africa - Oncopeptides
- Extraordinary General Meeting in Oncopeptides AB (publ) - Oncopeptides
- Oncopeptides carries out a fully guaranteed rights issue of approximately SEK 300 million to reach profitability during 2026 - Oncopeptides
- Oncopeptides receives decision from the U.S. Food and Drug Administration confirming withdrawal of Pepaxto from the U.S. market - Oncopeptides
- Oncopeptides receives positive recommendation for Pepaxti by Spanish Pricing Authority - Oncopeptides
- Oncopeptides’ PORT study shows peripheral administration of Pepaxti being equally safe as central venous administration - Oncopeptides
- Oncopeptides publishes year-end report 2023 - Oncopeptides
- Pepaxti provides sustained health related Quality of Life OCEAN study shows, article published in Haematologica - Oncopeptides
- View more press releases Close
关于 Oncopeptides 的社交媒体
保持联系
通过电子邮件联系联系该企业高管，包括 Sofia Heigis 
